Article Text

OP0011 Inequalities across 46 european countries in clinical eligibility criteria for the start of a first (reimbursed) biologic in patients with rheumatoid arthritis
  1. P. Putrik1,
  2. S. Ramiro2,
  3. T. Kvien3,
  4. T. Uhlig3,
  5. A. Boonen4
  6. and Working Group Equity in Clinical Eligibility Criteria for RA Treatment
  1. 1Health Promotion and Education, Maastricht University, Maastricht, Netherlands
  2. 2Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal
  3. 3Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
  4. 4Division of Rheumatology, MUMC, Maastricht, Netherlands


Background In the treatment of patients with RA, strategies that include biologics have resulted in a better outcome for patients with regard to disease activity, need for surgery and work participation. Across the countries, reimbursement criteria and/or recommendations/guidelines have been formulated to regulate access to these costly treatments.

Objectives To explore clinical eligibility criteria for the start of a first reimbursed biologic in patients with RA and compare them across different European countries.

Methods A questionnaire was sent via email to one representative rheumatologist in 48 countries of the European Region to collect data on the eligibility criteria for a first biologic in patients with RA, as of May 2011. First, rheumatologists were asked whether either reimbursement or clinical recommendations or both were mainly regulating prescription in clinical practice. Further information was collected on (a) minimal disease duration required, (b) number of previous DMARDs needed to be failed and (c) requirements for disease activity or severity, mandatory before the start of a biological. A simple score was developed to evaluate the level of restrictions in access to reimbursed biologics across the countries (table). This score varied between 0 and 5, the higher the score, the easier the access. Results are presented using descriptive statistics.

Results Forty-six countries (response rate 96%) provided data. In 10 countries (22%) no biologic was reimbursed. Among the remaining 36, Luxemburg had no regulation of access to reimbursed biologics, in 13 (36%) the reimbursement criteria were the major source of eligibility criteria, while in 7 (19%) the clinical recommendations predominated, and in 15 (42%) both reimbursement criteria and clinical recommendations were used (usually because they were similar).

Among those with at least 1 biologic reimbursed, 20 countries (56%) had no requirement for disease duration in order to initiate a biologic, and for the remaining countries a duration of 3 to 12 months was mandatory. The majority of the countries (47%) required a failure of 2 synthetic DMARDs to qualify for therapy with biologics. Thirty out of 36 countries specified a minimum level of disease activity that had to be fulfilled before treatment with biologics (table).

Three countries (8%) had the maximum (5) eligibility score (most liberal), 19% had a score of 4, 22% a score of 3, 17% a score of 2, 28% of 1 and 6% (2 countries) a score of 0 (more restrictive). Countries from Eastern Europe and former Soviet Union were more likely to be classified in the more restricted scores.

Conclusions Clinical criteria for biologic therapy differ significantly across the countries, indicating inequalities in access to treatment in RA. These findings should alert stakeholders to further strive for optimal standards of rheumatologic care and implement them across all European countries.

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.